Breaking the Undruggable: How a New Drug Targeting KRAS Transforms Pancreatic Cancer Treatment
A Paradigm Shift in pancreatic cancer treatment
For decades, pancreatic cancer has been one of oncology's most stubborn challenges. A new drug called daraxonrasib has now achieved what researchers once considered impossible: successfully targeting the KRAS mutation that drives the majority of pancreatic tumors. In a landmark clinical